Posts by: David Melamed, PhD

David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

November 9, 2020November 9, 2020

New Nirogacestat Combos to Enter Myeloma Trials, SpringWorks Says

News

SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents to treat people with relapsed or refractory multiple ... Read more

March 2, 2020March 2, 2020

Loss of Specific Gene May Help Drive Myeloma Progression, Study Finds

News

One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13, and researchers now suggest that the loss of one ... Read more

February 12, 2020February 12, 2020

Phase 1/2 Trial of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma to Open Soon

News

A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed or refractory multiple myeloma. The Phase 1/2a trial (NCT04171843) is expected to begin ... Read more

February 7, 2020February 7, 2020

Advancing Novel Cell Therapy for Myeloma and Multiple Cancers Goal of New Partnership

News

A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf cell therapy designed to treat multiple types of cancers, including multiple myeloma, the companies announced. The ... Read more

January 20, 2020January 20, 2020

NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients

News

NexImmune will soon initiate a Phase 1/2 trial evaluating its cell therapy NEXI-002 in people with multiple myeloma who failed three or more prior lines of therapy, the company ... Read more